07_Depression_SSRIs_and_SNRIs

SSRIs (Selective Serotonin Reuptake Inhibitors) and SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) are first-line medications prescribed for the management of depression and anxiety disorders. Their mechanism focuses on the modulation of neurotransmitters associated with mood regulation.
Key Neurotransmitter:
- Serotonin (5-HT) plays a crucial role in regulating mood, anxiety, and overall emotional state. Evidence suggests that low levels of serotonin contribute significantly to the risk of developing depressive symptoms, which is a primary target for these medications.

SSRIs primarily function by selectively inhibiting the serotonin transporter on presynaptic neurons, leading to an increase in serotonin levels in the synaptic cleft. This inhibition results in more serotonin being available to bind to postsynaptic receptors, thereby enhancing serotonergic neurotransmission and promoting mood improvement.

Box Warnings and Contraindications:
- There is a potential risk of developing serotonin syndrome, a life-threatening condition associated with excessive serotonergic activity, particularly when SSRIs are used in conjunction with other serotonergic medications.
- It is critical to avoid coadministration of SSRIs with MAO inhibitors, linezolid, and intravenous methylene blue due to the high risk of serotonin syndrome.
- SSRIs are contraindicated in patients taking Pemazide due to the risk of toxicity from the interaction.
Warnings:
- QT Prolongation:
- QT prolongation is characterized by a prolongation of the QT interval to greater than 440 ms, which can lead to serious heart conditions like Torsades de Pointes when QT exceeds 500 ms.
- The risk of QT prolongation is notably heightened with high doses of citalopram and escitalopram.
- Recommended maximum doses are:
  - Citalopram: $40 ext{ mg/day}$
  - Escitalopram: $20 ext{ mg/day}$
- It is advisable to consider halving the doses for patients aged over 60 years due to an increased sensitivity to these side effects.

Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH):
- This condition can develop as a result of SSRI treatment, leading to hyponatremia (low sodium levels in the blood) due to excess water retention, which may result in neurological complications if not managed appropriately.
Bleeding Risk:
- The concomitant use of SSRIs with other medications that affect bleeding, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or anticoagulants, can significantly raise the risk of hemorrhagic events, necessitating careful monitoring and assessment.

Common side effects of SSRIs include:
- Sexual Dysfunction: A frequent adverse effect characterized by low libido, difficulties with ejaculation, and erectile dysfunction, which can adversely affect medication adherence.
- Additional central nervous system (CNS) effects may manifest as somnolence, insomnia, dizziness, headache, weakened physical state, tremors, nausea, and dry mouth, affecting overall quality of life.

Fluoxetine:
- Recognized as an activating agent, it is best administered in the morning to prevent sleep disturbances.
- Its long half-life allows for the possibility of discontinuation without a tapering schedule.
- It has a unique indication for the treatment of premenstrual dysphoric disorder (PMDD).
Paroxetine:
- Noteworthy for its more prominent anticholinergic properties and sedative effects, making it preferable to take in the evening.
- This medication is contraindicated in pregnancy, posing risks to fetal development.
Escitalopram & Citalopram:
- Careful attention to dosing is warranted for these medications owing to their association with QT prolongation risks.

SNRIs block the reuptake of both serotonin and norepinephrine, enhancing the overall neurotransmitter availability that contributes to mood elevation.
Monitoring blood pressure is essential during treatment, as an increase can be a significant concern, especially in patients with pre-existing hypertension.
Commonly observed side effects include increased heart rate, dry mouth, and constipation, which should be discussed with patients during consultations.
Venlafaxine:
- The immediate release formulation should be limited to doses of less than $375 ext{ mg/day}$ to reduce risks of side effects.
- It is also effective in treating anxiety disorders in addition to depressive symptoms.
Duloxetine:
- Notably indicated for pain conditions such as diabetic neuropathy and fibromyalgia, demonstrating its versatility beyond mood disorders.

Similar to SSRIs, SNRIs exhibit interactions that necessitate vigilance.
- Increased risk of serotonin syndrome due to additive effects with other serotonergic drugs should be closely monitored.
- There is a particular risk associated with MAO inhibitors; appropriate washout periods are essential to prevent adverse events, with standard washout being 2 weeks and a prolonged 5 weeks for Fluoxetine.
CYP2D6 Inhibition:
- SSRIs can inhibit the metabolism of various drugs, such as tamoxifen, preventing its conversion into the active therapeutic form, which is critical in breast cancer treatment.
Antidepressant Choice with Tamoxifen:
- It is recommended to utilize Venlafaxine in lieu of SSRIs when treating patients also taking tamoxifen to mitigate metabolic interference and maximize therapeutic efficacy.

Example scenario: A patient currently on phenelzine is prescribed Celexa (citalopram). It is crucial to counsel the patient to discontinue phenelzine and allow a waiting period of two weeks for safety precautions due to the risk of serotonin syndrome.

In summary, SSRIs and SNRIs serve as foundational agents in the therapeutic landscape for depression, requiring a thorough understanding of their safety profiles, effectiveness, side effects, and potential drug interactions for optimal clinical management. It is vital to stay informed about ongoing research and changes in guidelines to provide the best patient care possible.
Future topics will delve into tricyclic antidepressants and their unique therapeutic profiles.